PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation

Nucleic Acids Research

Volumn 39, Issue 12, 2011, Pages 5284-5298

  Ezzat, Kariem ^a   El Andaloussi, Samir ^b   Zaghloul, Eman M ^b   Lehto, Taavi ^c   Lindberg, Staffan ^a   Moreno, Pedro M D ^b   Viola, Joana R ^b   Magdy, Tarek ^a   Abdo, Rania ^a   Guterstam, Peter ^a   Sillard, Rannar ^a   Hammond, Suzan M ^d   Wood, Matthew J A ^d   Arzumanov, Andrey A ^e   Gait, Michael J ^e   Smith, C I Edvard ^b   Hällbrink, Mattias ^a,f   Langel, Ülo ^a,c  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF TARTU   (Estonia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

^f Cepep II AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA GLOBIN; CELL PENETRATING PEPTIDE; CHLOROQUINE; LACTOSE; LIPOFECTAMINE; MACROGOL 6000; MANNITOL; MESSENGER RNA; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PEPFECT 14; PHOSPHOROTHIOATE 2' O METHYL RNA ANTISENSE OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DISPERSION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DUCHENNE MUSCULAR DYSTROPHY; ENDOCYTOSIS; EXON SKIPPING; FEASIBILITY STUDY; HUMAN; HUMAN CELL; INTRON; MOUSE; MYOTUBE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZETA POTENTIAL;

EID: 79960250118     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkr072     Document Type: Article

References (40)

1. Munos, B. (2009) Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov., 8, 959-968.
2. Butler, D. (2008) Translational research: crossing the valley of death. Nature, 453, 840-842. (Pubitemid 351832542)
3. Nilsen, T.W. and Graveley, B.R. (2010) Expansion of the eukaryotic proteome by alternative splicing. Nature, 463, 457-463.
4. Sazani, P. and Kole, R. (2003) Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest., 112, 481-486. (Pubitemid 38056330)
5. Bauman, J., Jearawiriyapaisarn, N. and Kole, R. (2009) Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides, 19, 1-13.
6. Wood, M.J. (2010) Toward an oligonucleotide therapy for duchenne muscular dystrophy: a complex development challenge Sci. Transl. Med., 2, 25ps15.
7. Ivanova, G.D., Arzumanov, A., Abes, R., Yin, H., Wood, M.J., Lebleu, B. and Gait, M.J. (2008) Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res., 36, 6418-6428.
8. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., van der Kooi, A.J., Goemans, N.M. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med., 357, 2677-2686.
9. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P. et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol., 8, 918-928.
10. Bell, N.M. and Micklefield, J. (2009) Chemical modification of oligonucleotides for therapeutic, bioanalytical and other applications. Chembiochem, 10, 2691-2703.
11. Amidon, G.L., Lennernas, H., Shah, V.P. and Crison, J.R. (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420.
12. Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 46, 3-26. (Pubitemid 33653411)
13. Dass, C.R. (2004) Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J. Mol. Med., 82, 579-591. (Pubitemid 39312663)
14. Ezzat, K., El Andaloussi, S., Abdo, R. and Langel, Ü . (2010) Peptide-based matrices as drug delivery vehicles. Curr. Pharm. Des., 16, 1167-1178.
15. Heitz, F., Morris, M.C. and Divita, G. (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol., 157, 195-206.
16. Wood, M.J., Gait, M.J. and Yin, H. (2010) RNA-targeted splice-correction therapy for neuromuscular disease. Brain, 133, 957-972.
17. Lehto, T., Abes, R., Oskolkov, N., Suhorutsenko, J., Copolovici, D.M., Mäger, I., Viola, J.R., Simonson, O.E., Ezzat, K., Guterstam, P. et al. (2010) Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J. Control. Release, 141, 42-51.
18. Deshayes, S., Morris, M., Heitz, F. and Divita, G. (2008) Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv. Drug Deliv. Rev., 60, 537-547. (Pubitemid 351222678)
19. Mäe, M., Andaloussi, S.E., Lehto, T. and Langel, Ü . (2009) Chemically modified cell-penetrating peptides for the delivery of nucleic acids. Expert Opin. Drug Deliv., 6, 1195-1205.
20. Futaki, S., Ohashi, W., Suzuki, T., Niwa, M., Tanaka, S., Ueda, K., Harashima, H. and Sugiura, Y. (2001) Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug. Chem., 12, 1005-1011. (Pubitemid 33136872)
21. Mäe, M., El Andaloussi, S., Lundin, P., Oskolkov, N., Johansson, H.J., Guterstam, P. and Langel, Ü . (2009) A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J. Control. Release, 134, 221-227.
22. Guterstam, P., Lindgren, M., Johansson, H., Tedebark, U., Wengel, J., El Andaloussi, S. and Langel, Ü. (2008) Splice-switching efficiency and specificity for oligonucleotides with locked nucleic acid monomers. Biochem. J., 412, 307-313. (Pubitemid 351758236)
23. Lu, Q.L., Rabinowitz, A., Chen, Y.C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G. and Partridge, T. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl Acad. Sci. USA, 102, 198-203. (Pubitemid 40094452)
24. Coin, I., Beyermann, M. and Bienert, M. (2007) Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat. Protoc., 2, 3247-3256.
25. Morgan, J.E., Beauchamp, J.R., Pagel, C.N., Peckham, M., Ataliotis, P., Jat, P.S., Noble, M.D., Farmer, K. and Partridge, T.A. (1994) Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev. Biol., 162, 486-498. (Pubitemid 24144125)
26. Kang, S.H., Cho, M.J. and Kole, R. (1998) Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry, 37, 6235-6239. (Pubitemid 28213640)
27. Molina, M.D. and Anchordoquy, T.J. (2008) Degradation of lyophilized lipid/DNA complexes during storage: the role of lipid and reactive oxygen species. Biochim. Biophys. Acta, 1778, 2119-2126.
28. Yu, J. and Anchordoquy, T.J. (2009) Synergistic effects of surfactants and sugars on lipoplex stability during freeze-drying and rehydration. J. Pharm. Sci., 98, 3319-3328.
29. El Andaloussi, S., Lehto, T., Mäger, I., Rosenthal-Aizman, K., Oprea, J., Simonson, O.E., Sork, H., Ezzat, K., Copolovici, D.M., Kurrikoff, K. et al. (2011) Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res., doi:10.1093/nar/gkq1299 [Epub ahead of print].
30. Ramsay, E. and Gumbleton, M. (2002) Polylysine and polyornithine gene transfer complexes: a study of complex stability and cellular uptake as a basis for their differential in-vitro transfection efficiency. J. Drug Target., 10, 1-9. (Pubitemid 34223844)
31. Hällbrink, M., Oehlke, J., Papsdorf, G. and Bienert, M. (2004) Uptake of cell-penetrating peptides is dependent on peptide-to-cell ratio rather than on peptide concentration. Biochim. Biophys. Acta, 1667, 222-228. (Pubitemid 39576087)
32. Alam, M.R., Dixit, V., Kang, H., Li, Z.B., Chen, X., Trejo, J., Fisher, M. and Juliano, R.L. (2008) Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res., 36, 2764-2776. (Pubitemid 351659588)
33. Vasconcelos, T., Sarmento, B. and Costa, P. (2007) Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today, 12, 1068-1075. (Pubitemid 350186132)
34. Son, K.K., Patel, D.H., Tkach, D. and Park, A. (2000) Cationic liposome and plasmid DNA complexes formed in serum-free medium under optimum transfection condition are negatively charged. Biochim. Biophys. Acta, 1466, 11-15. (Pubitemid 30312960)
35. Son, K.K., Tkach, D. and Hall, K.J. (2000) Efficient in vivo gene delivery by the negatively charged complexes of cationic liposomes and plasmid DNA. Biochim. Biophys. Acta, 1468, 6-10.
36. Ahuja, S. and Scypinski, S. (2001) Handbook of Modern Pharmaceutical Analysis. Academic Press, San Diego.
37. Molina, M.C. and Anchordoquy, T.J. (2007) Metal contaminants promote degradation of lipid/DNA complexes during lyophilization. Biochim. Biophys. Acta, 1768, 669-677. (Pubitemid 46275603)
38. Armstrong, T.K. and Anchordoquy, T.J. (2004) Immobilization of nonviral vectors during the freezing step of lyophilization. J. Pharm. Sci., 93, 2698-2709. (Pubitemid 39506620)
39. Molina, M.C., Armstrong, T.K., Zhang, Y., Patel, M.M., Lentz, Y.K. and Anchordoquy, T.J. (2004) The stability of lyophilized lipid/DNA complexes during prolonged storage. J. Pharm. Sci., 93, 2259-2273. (Pubitemid 39129624)
40. Brus, C., Kleemann, E., Aigner, A., Czubayko, F. and Kissel, T. (2004) Stabilization of oligonucleotide-polyethylenimine complexes by freeze-drying: physicochemical and biological characterization. J. Control. Release, 95, 119-131. (Pubitemid 38167686)